Key Challenges in Implementing Liquid Biopsy in Clinical Practice

It is considered as an important tool in the non-invasive method of cancer detection, personalized treatment, and monitoring. The widespread adoption of liquid biopsy in clinical practices will come with a lot of challenges. These barriers will come from a various ranges from regulatory to cost related issues. As the demand for biopsy grows researchers and companies are utilizing their full potential to overcome these challenges. This blog will provide an overview about the challenges that are faced in the implementation of liquid biopsy, and how these issues can be solved. To know more details about the liquid biopsy market kindly visit to the report published by Coherent Market Insights.

Adoption Barriers in Liquid Biopsy:

The widespread adoption of liquid biopsy will comes will a lot of barriers. Healthcare providers and institution are not much familiar with the use of this new technology and uncertain with its clinical validation. Liquid biopsies in its early stage will provide clinical value across the various types of cancers and stages of diseases. The medical community to use liquid biopsy will require a standardized protocol before they are committing with the integration of liquid biopsy in their clinical routine.

Liquid Biopsy Clinical Hurdles:

The most pressing challenge in the field of clinical implementation of liquid biopsy is the demand for accuracy and consistency. Current methods that helps in extraction and analyse are ctDNA and ctRNA these are collected from the blood sample that lacks precision require for the process of effective decision making in the field of cancer treatment. In Addition, the result of liquid biopsy will be effected by a range of factors such as stage of disease, type of cancer, tumor heterogeneity. This makes the use of these test difficult to monitor and diagnose the diverse range of patients.

However, the clinical hurdels in the field of liquid biopsy are frequency for testing and appropriate time. The ability of liquid biopsy methods to monitor minimum residuals disease and detect the recurrence of cancer is in its evolving stage.

Regulatory Issues in Liquid Biopsy:

The other challenge in the field of liquid biopsy is the regulatory approval. The regulatory landscape of liquid biopsy is still in its evolving phase. The major international and regulatory bodies in the U.S. are not clear with the guidelines and approval need for the validation of biopsy test. The uncertain surrounding in the regulatory process create delays in bringing the liquid biopsy technologies in the clinical market.

Companies are closed working with the FDA and other regulatory bodies as they are evaluating liquid biopsy and navigating the approval process. However, clinical regulatory require a regulatory framework that ensure that these test are meeting the standards related to the safety and efficacy of patients.

Cost of Liquid Biopsy Technology:

Cost is considered as another obstacle while implementing the liquid biopsy technology. The liquid biopsy process in non-invasive in nature and it is able to reduce cost in long run. The high amount of investment and operational cost for testing in expensive for the clinics and hospitals.

Researcher and companies are putting their full efforts to reduce the cost via some innovative technologies and efficient workflows. As the technology continues to evolve, the cost decrease and makes these liquid biopsy process more accessible of patients and hospitals.